Swiss HealthTech startup PeakData raised €12.1 million ($12 million) in a Series A round led by AlbionVC, which also saw participation from Octopus Ventures and Heal Capital.
PeakData has developed an artificial intelligence (AI) platform that identifies and monitors the most relevant and impactful healthcare professionals (HCP) for pharmaceutical companies to connect with, Tech Funding News reported Monday (Aug. 22).
Using the platform, pharmaceutical companies can track and gain insight into the HCPs most relevant to their projects. Per the report, the platform uses AI to rank HCPs in terms of their digital impact, influence and relevance to their target market, tracking their status over time.
“We see PeakData as filling a key gap in the way our customers receive and analyze this data in order to improve the conversations they are having with a much wider variety of HCPs in their area,” said Patrick De Boer, co-founder of PeakData.
PeakData plans to use the new capital to expand all aspects of its business, support its growth plans and continue to develop the platform. The report noted that the company is aiming to have its platform in as many drug markets as possible in the next five years.
Christoph Ruedig, partner at AlbionVC, said that “finding the right therapeutic experts and healthcare professionals for their medicines is massively important for pharmaceutical companies and with PeakData they can now reach global, national, and local medical professionals who shape clinical decision-making.”
As PYMNTS reported recently, a string of data breaches have sent shockwaves through the healthcare industry, with implications for businesses’ finances and reputations.
According to a study in HIPAA Journal, “From July 2021 to June 2022, 692 large healthcare data breaches have been reported and the records of 42,431,699 individuals have been exposed or impermissibly disclosed.”
Just like healthcare providers, pharmaceutical companies will look to partner only with companies that have a strong track record of cybersecurity.
For all PYMNTS EMEA coverage, subscribe to the daily EMEA Newsletter.
PARTNER WITH PYMNTS